July 22, 2025
Recent results from the Phase 2 Apa-RP trial presented in May 2024 evaluated Erleada (apalutamide) combined with androgen-deprivation therapy (ADT) as an adjuvant treatment following radical prostatectomy in patients with high-risk localized prostate cancer. The study enrolled 108 patients and reported that all participants remained free of biochemical recurrence at the 24-month follow-up, translating to a biochemical recurrence-free survival rate of 100%. Additionally, the majority (76.4%) of patients achieved testosterone recovery within 12 months, reflecting minimal long-term hormonal suppression. The adverse event profile was manageable, with approximately 22% of participants experiencing Grade 3–4 adverse events, consistent with previously reported tolerability data. These findings underscore the potential of Erleada-based adjuvant therapy to effectively prevent recurrence in a patient population traditionally at high risk for relapse post-surgery.
Citation: Fierce Pharma, 2024; Globe Newswire, 2024. Available at: https://www.fiercepharma.com/pharma/johnson-johnsons-erleada-prevails-over-astellas-and-pfizers-xtandi-real-world-prostate; https://www.globenewswire.com/news-release/2024/05/03/2875293/0/en/Phase-2-data-for-ERLEADA-apalutamide-plus-androgen-deprivation-therapy-following-radical-prostatectomy-in-patients-with-high-risk-localised-prostate-cancer-shows-100-percent-bioche.html
Implication: These positive outcomes may significantly influence postoperative adjuvant treatment guidelines, emphasizing early intervention.